WeChat-Based Intervention

Uses

How it works

Dosage & preparation

Preparation

Comparisons

Highlighted claims

• The intervention is an 18-week weekly ePRO symptom-monitoring programme delivered through a WeChat-based PRIME-HCC platform. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
• Participants in the intervention group complete weekly symptom surveys. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
• When symptom scores exceed predefined thresholds, the platform alerts patients and provides automated evidence-based self-management advice. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
• WeChat was selected because it is widely used in China and works with mobile phones and tablets. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
• PRIME-HCC tests a patient-directed alert model intended to reduce provider workload and cost. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
• After each weekly survey, participants receive a personalized visual symptom report including score, concerning patterns, and trend graph. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial